N/A
Completed N=365
Bevacizumab in Metastatic Renal Cancer
Source: ClinicalTrials.gov NCT02627144 ↗Enrolled (actual)
365
Serious AEs
20.1%
Results posted
Jul 2016
Primary outcomePrimary: Percentage of Participants With Best Overall Tumor Response — 5.3; 21.9; 39.1; 16.6 percentage of participants
Summary
This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Best Overall Tumor Response |
5.3; 21.9; 39.1; 16.6; 17.2 | — |
| PRIMARY Percentage of Participants With Disease Control |
66.3 | — |
| PRIMARY Progression-free Survival (PFS) Time |
10.2 | — |
| PRIMARY Overall Survival (OS) Time |
28.7 | — |
| PRIMARY Cumulative Dose of Immunotherapy (Interferon Alpha-2a) in Daily Routine |
— | — |
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed advanced and/or metastatic renal cell cancer
- No contraindications for Avastin according to summary of product characteristics (SmPC)
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT02627144). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.